Clinical pharmacology and therapeutics, 2011-12, Vol.90 (6), p.774-776
2011
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Unveiling the Mysteries of Clopidogrel Metabolism and Efficacy
- Ist Teil von
- Clinical pharmacology and therapeutics, 2011-12, Vol.90 (6), p.774-776
- Ort / Verlag
- United States
- Erscheinungsjahr
- 2011
- Quelle
- Wiley Blackwell Single Titles
- Beschreibungen/Notizen
- Clopidogrel is an important antiplatelet agent, but a considerable variability in the biological effect of the drug has been observed. Additionally, patients with insufficient platelet reactivity inhibition following a loading dose (LD) of clopidogrel have a poor outcome. The mechanisms of variability are dependent on genetic polymorphisms of enzymes involved in clopidogrel metabolism. Paraoxonase 1 has been identified as the main determinant of the biological and clinical efficacy of clopidogrel. This finding could enable the use of pharmacogenomics to tailor antiplatelet agents. Clinical Pharmacology & Therapeutics (2011); 90 6, 774–776. doi:10.1038/clpt.2011.222
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0009-9236eISSN: 1532-6535DOI: 10.1038/clpt.2011.222Titel-ID: cdi_proquest_miscellaneous_905677322
- Format
- –
- Schlagworte
- Aryldialkylphosphatase - genetics, Cardiovascular Diseases - genetics, Cardiovascular Diseases - mortality, Female, Genetic Association Studies - methods, Genetic Variation - genetics, Humans, Male, Myocardial Infarction - drug therapy, Myocardial Infarction - genetics, Polymorphism, Genetic - genetics, Ticlopidine - analogs & derivatives